Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-67

Yes we should be used to that by now..Announcement drops we drop..

The SP action is as usual...but some volume today ...I think it won't go down too far...news is mix of positive and negative as Sam has addressed.

My take ...I m still positive as the trial is still being initiated very soon...Pharmas can wait for the results in a year time but if we get any decent progress midway the partnership $$ will just go up...

I have always been confident on trial results ( based on OZ trial results. Prometrics data etc etc) ...it's just the matter of starting the trial / first dose and with today's announcement it's clear that they are starting ( planning ) in the next few months ....

" Trial anticipated to start in Q4 2022 "

Imo dyor..